Dialysis industry news

Stories from the dialysis comunity across the globe.



Prostate Cancer Treatment May Increase Colorectal Cancer Risk - Renal and Urology News PDF Print
June 22, 2015 Prostate Cancer Treatment May Increase Colorectal Cancer Risk - Renal and Urology News
Researchers observed greater incidences of colorectal cancer among patients who underwent bilateral orchiectomy, surgery, and ADT.

Prostate cancer (PCa) patients who undergo bilateral orchiectomy, radical prostatectomy, or other treatments may be at increased risk of colorectal cancer, a new Swedish study suggests.

A team led by Yunxia Liu, MD, of Karolinska Institutet in Stockholm, used data from 3 national Swedish health registries to calculate the incidence of colorectal adenocarcinoma among 149,743 PCa patients, compared with the general Swedish male population. The investigators divided subjects into 4 groups: group 1, diagnosed between 1961 and 1980, historically received estrogen; whereas groups 2, 3, and 4, diagnosed between 1981 and 2008, underwent bilateral orchiectomy, prostatectomy, and other treatment (mainly gonadotropin-releasing hormone agonists, radiotherapy, or both). Over 601,542 person-years of follow-up, 1,698 patients were diagnosed with colorectal adenocarcinomas.

Compared with the general male population, patients treated with bilateral orchiectomy, prostatectomy, and other non-estrogen treatments had a 30%, 22%, and 37% increased incidence of colorectal cancer, respectively, according to an online report in Cancer Control.

No clear association was found among group 1 patients treated with estrogen. The researchers noted that previous studies in women have linked higher levels of estrogen and progesterone to lower risk of colorectal cancer.

“Treatment for prostate cancer diagnosed after 1980 may be associated with an increased risk of adenocarcinoma, implying a possible connection to ADT, one of the most common treatments in Sweden used after 1980,” the researchers stated. The increased risk among orchiectomy patients could be related to surgical androgen deprivation, they posited, and the risk among non-surgery patients could be due to medically induced androgen deprivation.

Greater risks were observed in cases of adenocarcinoma of the distal colon and rectum than in the proximal colon. The investigators hypothesize that genetic and/or physiological mechanism may explain the differences because the gut originates from different parts of a developing embryo.

The researchers pointed out the strengths of the study, including its nationwide and population-based cohort design identified by from national registries, its large PCa cohort sizes, and long and complete follow-up times. They also acknowledged limitations, such as the absence of detailed information on hormonal treatments such as estrogen or anti-androgen medications.

Source
  1. Lu, Y, et al. Cancer Control, April 2015.

...

 
FDA Seizes Counterfeit ED Medications, More - Renal and Urology News PDF Print
June 22, 2015 diabetes-medication-adherence
diabetes-medication-adherence

(HealthDay News) -- The U.S. Food and Drug Administration, along with international partners, moved this week against more than 1,050 websites that sell potentially dangerous counterfeit medicines and medical devices, the agency said Thursday.

Illegal medicines and medical devices were seized worldwide, and warnings were sent to the operators of offending websites, the FDA said in a news release. "Our efforts to protect the health of American patients by preventing the online sale of potentially dangerous illegal medical products will not cease," George Karavetsos, director of the FDA's Office of Criminal Investigations, said in the news release.

Counterfeit prescription drugs that claim to be generic versions of brand-name drugs that are sold illegally on the websites include generic Nolvadex, generic Meridia, generic Valium, generic Truvada, and generic Advair Diskus, according to the FDA. Mail screenings in Chicago, Miami, and New York found that some of these counterfeit drugs -- which included antidepressants, hormone replacement therapies, sleep aids, and drugs to treat erectile dysfunction, high cholesterol, and seizures -- were on their way to American consumers, the FDA said. Bogus medical devices sold on websites that were targeted include hyaluronic acid and other dermal fillers and "colon hydrotherapy" products.

As part of the international effort led by Interpol, the FDA said it sent warning letters to the operators of nearly 400 websites selling unapproved or misbranded prescription medicines to U.S. consumers, and to 9 companies distributing unapproved medical devices online.

Source

  1. FDA News Release, June 18, 2015.

...

 
Dialysis topples childbirth from top spot in Philhealth - Sun.Star PDF Print

INCIDENTS of kidney disease continue to rise in the Philippines, the Department of Health's Renal Disease Control Program in Davao Region said.

The number is growing so fast such that records from the Philippine Health Insurance Corporation (Philhealth) show that dialysis patients are now the number one in terms of accounts served by Philhealth, outranking childbirth that has been number one for decades past.

Davao kidney specialist consultant Dr. Franklin Guillano earlier cited a report from Philippine Renal Disease Registry that around 1,000 patients in Davao Region are undergoing a maintenance dialysis mostly from Davao City.

Redcop spokesperson Dr. Maria Theresa Lorenzo Bad-ang said there is an increase of 15 percent of people diagnosed with kidney disease based on a data from the Philippine Renal Disease Registry in 2013 as compared to 2012.

Bad-ang said that in 2013, 14,395 new patients had to have dialysis, for a total of 23,364 patients nationwide. In 2012, the new patients numbered 12,500.

In Davao City, 800 kidney disease cases have been recorded of which 20 have undergone kidney transplant.

It was also reported that Davao Region ranks number four in the number of kidney patients nationwide as of 2014. On the top spot is the National Capital Region followed by Region 4, and then the Bicol Region at third place.

Davao City Council Committee on Health chairperson Councilor Joselle Villafuerte emphasized that early prevention is much better, as she recommends a healthy lifestyle, proper food intake, and adequate intake of water.

The health officers also raised the importance in controlling the three major causes of the kidney disease: diabetes, hypertension, and chronic glomerulonephritis.

On top of the list to be removed from one's diet to prevent kidney diseases are junk food and soft drinks. Both children and adults are encouraged to undergo annual urinalysis.

...

 
Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Jeffrey ... - OTC Outlook PDF Print

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Jeffrey H Burbank , Chief Executive Officer of Nxstage Medical, Inc. sold 20,000 shares on Jun 17, 2015. The Insider selling transaction was disclosed on Jun 19, 2015 to the Securities and Exchange Commission. The shares were sold at $15.56 per share for a total value of $311,200.00 according to InsiderTradingReport.

12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 477,362 and an average 10 day volume is recorded to be 425,475 The Company has disclosed insider buying and selling activities to the Securities Exchange,The (President) of Nxstage Medical, Inc., Turk Joseph E Jr sold 2,839 shares at $16 on June 10, 2015. The Insider selling transaction had a total value worth of $45,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. NxStage Medical, Inc. (NASDAQ:NXTM) witnessed a volatile trading activity on Friday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $15.75 and reached the intraday high at $15.9. The bulls started the profit booking and pushed the shares to intraday low of $15.67. The trading session was marked by a volume range of 569,907 shares exchanging hands. The 52-week high of the shares is $19.63 and the 52-week low is $11.5. The market cap of the company stands at $993 million and there are 63,238,000 shares in public circulation. The shares of NXTM have rallied 12.35% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $16.9 and the 200 day moving average is recorded at $17.56. S&P 500 has rallied 8.07% during the last 52-weeks. Several Brokerage firms have commented on company shares. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM).The analysts at the brokerage house have a current rating of Buy on the counter. In a recent information released to the investors, Canaccord Genuity raises the new price target from $24 per share to $27 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...

 
Company Shares of Rockwell Medical, Inc. Rally 5.86% - American Trade Journal PDF Print

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 5.86% in the past week and 34.16% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 5.06% and the outperformance increases to 35.18% for the last 4 weeks. For the current week, the company shares have a recommendation consensus of Buy.

18.55% of the shares are held by the company Insiders, 28% of the shares are held by the institutions. Company shares has an average 3 month share volume of 564,811 and an average 10 day volume is recorded to be 898,625 Shares of the company have rallied 22.18% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $14.95 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.32 and the 200 day moving average is recorded at $10.48. S&P 500 has rallied 7.51% during the last 52-weeks. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Friday session in red amid volatile trading. The shares closed down 0.2 points or 1.4% at $14.1 with 557,110 shares getting traded. Post opening the session at $14.44, the shares hit an intraday low of $13.96 and an intraday high of $14.4484 and the price vacillated in this range throughout the day. The company has a market cap of $707 million and the number of outstanding shares has been calculated to be 50,169,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $14.95 and the 52-week low is $8.095. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
<< Start < Prev 141 142 143 144 145 146 147 148 149 150 Next > End >>

Page 148 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.